Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhao, Li ^a   Chen, Chunxia ^a   Li, Bei ^a   Dong, Li ^a   Guo, Yingqiang ^a   Xiao, Xijun ^a   Zhang, Eryong ^a   Qin, Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ACCURACY; ADULT; ALGORITHM; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYP2C9 GENE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DU ALGORITHM; ERROR; FEMALE; GAGE ALGORITHM; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAN CHINESE; HEART VALVE REPLACEMENT; HUANG ALGORITHM; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERNATIONAL WARFARIN PHARMACOGENETICS CONSORTIUM ALGORITHM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN ABSOLUTE ERROR; MECHANIC HEART VALVE REPLACEMENT; MIAO ALGORITHM; OBSERVATIONAL STUDY; PATIENT CODING; PHARMACOGENETICS BASED WARFARIN DOSING ALGORITHM; PREDICTIVE VALUE; VALIDATION PROCESS; VKORC1 GENE; WEI ALGORITHM; ZHANG ALGORITHM; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DOSE RESPONSE; ETHNIC GROUP; HEART VALVE PROSTHESIS; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; REPRODUCIBILITY; VALIDATION STUDY;

ALGORITHMS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; GENETIC ASSOCIATION STUDIES; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS; WARFARIN;

EID: 84899655266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094573     Document Type: Article

References (36)

1. Yoshizawa M, Hayashi H, Tashiro Y, Sakawa S, Moriwaki H, et al. (2009) Effect of VKORC1-1639 G. A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thrombosis research 124: 161-166.
2. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS genetics 5: e1000433.
3. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, et al. (2005) A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clinical medicine & research 3: 137-145.
4. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333.
5. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, et al. (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics and Genomics 5: 389-392.
6. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105: 645-649.
7. Yuan H-Y, Chen J-J, Lee MM, Wung J-C, Chen Y-F, et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human molecular genetics 14: 1745-1751.
8. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PloS one 7: e44064.
9. Miao L, Yang J, Huang C, Shen Z (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. European journal of clinical pharmacology 63: 1135-1141.
10. Huang S-W, Chen H-S, Wang X-Q, Huang L, Xu D-L, et al. (2009) Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenetics and genomics 19: 226-234.
11. Wei M, Ye F, Xie D, Zhu Y, Zhu J, et al. (2012) A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and haemostasis 107: 1083.
12. Zhang Y, Cui W, Han M, Zheng B, Liu F, et al. (2010) [Gene polymorphism of CYP450 2C9 and VKORC1 in Chinese population and their relationships to the maintaining dosage of warfarin]. Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi 31: 218-222.
13. Lou Y (2012) The Study of Warfarin Maintenance Dose Algorithm in Chinese Han Population: Peking Union Hospital.
14. Du L-P, Mei D, Liu C-W, Liu B, Su W, et al. (2010) Impact the gene polymorphisms of CYP 2C9 and VKORC1 on the warfarin dose and anticoagulation effect. Zhongguo yao xue za zai 45:1628.
15. Gu Q, Kong Y, Schneede J, Xiao Y-B, Chen L, et al. (2010) VKORC1-1639G. A, CYP2C9, EPHX1691A. G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. European journal of clinical pharmacology 66: 1217-1227.
16. Liang R, Li L, Li C, Gao Y, Liu W, et al. (2012) Impact of CYP2C93, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Journal of thrombosis and thrombolysis 34: 120-125.
17. Klein T, Altman R, Eriksson N, Gage B, Kimmel S, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England journal of medicine 360: 753-764.
18. Gage B, Eby C, Johnson J, Deych E, Rieder M, et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology & Therapeutics 84: 326-331.
19. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, et al. (2012) Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics 13: 1937-1950.
20. Ekladious SM, Issac MSM, Sharaf SAE-A, Abou-Youssef HS (2013) Validation of a Proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. Molecular diagnosis & therapy: 1-10.
21. Mazzaccara C, Conti V, Liguori R, Simeon V, Toriello M, et al. (2013) Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model. PloS one 8: e71505.
22. Roper N, Storer B, Bona R, Fang M (2010) Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. The Journal of Molecular Diagnostics 12: 283-291.
23. Shin J, Cao D (2011) Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 12: 125-134.
24. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, et al. (2012) A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) Clinical Perspective. Circulation 125: 1997-2005.
25. Gan GG, Teh A, Goh KY, Chong HT, Pang KW (2003) Racial background is a determinant factor in the maintenance dosage of warfarin. International journal of hematology 78: 84-86.
26. Li Y, Wang L, Jiang Y, Zhang M, Wang L (2013) Risk factors for noncommunicable chronic diseases in women in China: surveillance efforts. Bulletin of the World Health Organization 91: 650-660.
27. Fine LJ, Philogene GS, Gramling R, Coups EJ, Sinha S (2004) Prevalence of multiple chronic disease risk factors: 2001 National Health Interview Survey. American journal of preventive medicine 27: 18-24.
28. Ministry of Health (2007) Guidance on Chinese people's Meal Nutrition [R].
29. Tan S, Li Z, Song G, Liu L, Zhang W, et al. (2012) Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. Die Pharmazie-An International Journal of Pharmaceutical Sciences 67: 930-937.
30. Xu Q, Xu B, Zhang Y, Yang J, Gao L, et al. (2012) Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation. Thrombosis and haemostasis 108: 1132.
31. Liu Y, Yang J, Xu Q, Xu B, Gao L, et al. (2012) Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. Thrombosis research 130: 435-440.
32. ZHU J, ZHANG W, ZHANG W-J, WANG H-Y, WANG C (2011) Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms in Chinese Han Population. Chinese Pharmaceutical Journal 24: 019.
33. Food U (2009) Drug Administration: Table of valid genomic biomarkers in the context of approved drug labels. Accessed October.
34. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA (2009) Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. Journal of general internal medicine 24: 656-664.
35. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, et al. (2013) A randomized trial of genotype-guided dosing of warfarin. New England Journal of Medicine 369: 2294-2303.
36. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, et al. (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. New England Journal of Medicine 369: 2283-2293.